Price
$45.99
Increased by +0.48%
Dollar volume (20D)
54.86 M
ADR%
1.41
Earnings report date
Jun 17, 2024
Shares float
219.83 M
Shares short
2.91 M [1.32%]
Shares outstanding
221.85 M
Market cap
10.15 B
Beta
0.42
Price/earnings
30.11
20D range
39.64 46.01
50D range
39.03 46.01
200D range
34.77 47.04

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide.

The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.

In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions.

Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services.

It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers.

It has a collaboration with the U.S.

FBI.

The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Jun 17, 24 0.46
Decreased by -9.80%
0.44
Increased by +4.55%
Feb 6, 24 0.55
Increased by +3.77%
0.55
Oct 30, 23 0.50
Decreased by -5.66%
0.48
Increased by +4.17%
Aug 8, 23 0.51
Increased by 0.00%
0.50
Increased by +2.00%
May 3, 23 0.51
Decreased by -36.25%
0.47
Increased by +8.51%
Feb 7, 23 0.53
Decreased by -28.38%
0.47
Increased by +12.77%
Nov 7, 22 0.53
Decreased by -8.62%
0.45
Increased by +17.78%
Jul 28, 22 0.51
Decreased by -23.88%
0.46
Increased by +10.87%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 24 458.80 M
Decreased by -5.48%
80.67 M
Decreased by -5.13%
Increased by +17.58%
Increased by +0.37%
Dec 31, 23 509.16 M
Increased by +2.24%
97.66 M
Increased by +9.93%
Increased by +19.18%
Increased by +7.51%
Sep 30, 23 475.89 M
Decreased by -4.75%
77.82 M
Decreased by -5.55%
Increased by +16.35%
Decreased by -0.84%
Jun 30, 23 494.86 M
Decreased by -4.01%
80.79 M
Decreased by -16.42%
Increased by +16.33%
Decreased by -12.93%
Mar 31, 23 485.40 M
Decreased by -22.76%
85.03 M
Decreased by -45.25%
Increased by +17.52%
Decreased by -29.12%
Dec 31, 22 497.98 M
Decreased by -14.49%
88.84 M
Decreased by -31.23%
Increased by +17.84%
Decreased by -19.57%
Sep 30, 22 499.63 M
Decreased by -6.57%
82.39 M
Decreased by -38.11%
Increased by +16.49%
Decreased by -33.76%
Jun 30, 22 515.51 M
Decreased by -9.13%
96.66 M
Decreased by -20.15%
Increased by +18.75%
Decreased by -12.13%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY